- Salix's NDA for crofelemer in HIV-associated diarrhea assigned priority review status
- Genentech's BLA for pertuzumab receives priority review status in previously untreated HER2-positive metastatic breast cancer indication
- FDA reviewers questions efficacy of NeurogesX's Qutenza pain patch in proposed new use
- Shire's Vyvanse approved for maintenance treatment in adults with ADHD
- FDA accepts Ziopharm's IND application for oral formulation of Zymafos
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Home :: Cardiology :: Cardiology Conferences
American Heart Association Scientific Sessions 2008
November 8 - 12, 2008 New Orleans, LA- Drug-eluting stents do not increase risk of death, MI relative to bare-metal stents in patients with diabetes during long-term follow-up, analysis reveals
- Change in percent atheroma volume similar following treatment with rosiglitazone, glipizide in patients with type 2 diabetes, APPROACH data show
- OSA identified as novel risk factor for sudden cardiac death
- Irbesartan does not seem to reduce death, hospitalization in patients with preserved LVEF HF, study finds
- Safety, efficacy of interferon beta-1b for virus elimination in chronic viral cardiomyopathy confirmed in new trial
ACC's 57th Annual Scientific Session
March 29 - April 1 2008 Chicago, IL- CARISMA researchers use ILR to document arrhythmias in post-MI patients with low ejection fraction, identify high-degree AV block as independent predictor of cardiac death
- STRADIVARIUS trial fails to show effect of rimonabant in primary IVUS endpoint, but secondary endpoint data suggest drug might reduce atherosclerosis progression
- Experts discuss ENHANCE trial data, implications for clinical practice
- Cardiac resynchronization therapy might benefit asymptomatic, mildly symptomatic patients with HF, according to 12-month REVERSE trial data
- Door-to-needle, door-to-balloon times have decreased since 1990s
- Janssen submits sNDA for additional indication for Xarelto oral anticoagulant
- FDA revises label of Sanofi's Multaq heart drug to include restrictions
- Isis reports delay in submission of mipomersen NDA, adds three drugs to pipeline
- FDA approves Takeda's Edarbyclor for hypertension
- FDA grants fast track status to Celladon's Mydicar in HF
- LoneStar Heart acquires exclusive rights to potential diabetes drug class from UT Southwestern Medical Center
- AstraZeneca's Atacand associated with lower risk of all-cause mortality in patients with HF versus losartan, data suggest
- Janssen submits sNDA for additional indication for Xarelto oral anticoagulant
- Risk of acute coronary events observed with Boehringer Ingelheim's Pradaxa, analysis reveals
- Isis reports delay in submission of mipomersen NDA, adds three drugs to pipeline
